Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07791043 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)

Name: A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD) — clinical trial record (NCT07791043)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ALLSTAR

StatusNot Yet Recruiting

PhasePhase 2

SponsorGlaxoSmithKline

Started2026-09-23

View on ClinicalTrials.gov ↗

This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in participants with ALD.

Trial Details

NCT Number	NCT07791043
Lead Sponsor	GlaxoSmithKline
Conditions	Liver Diseases, Alcoholic
Enrollment	274 participants
Start Date	2026-09-23
Primary Completion	2028-09-05 (estimated)
Study Completion	2030-02-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-27